These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 38289338)

  • 1. Coupling of Slack and Na
    Yuan T; Wang Y; Jin Y; Yang H; Xu S; Zhang H; Chen Q; Li N; Ma X; Song H; Peng C; Geng Z; Dong J; Duan G; Sun Q; Yang Y; Yang F; Huang Z
    Elife; 2024 Jan; 12():. PubMed ID: 38289338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New use for an old drug: quinidine in KCNT1-related epilepsy therapy.
    Liu R; Sun L; Wang Y; Wang Q; Wu J
    Neurol Sci; 2023 Apr; 44(4):1201-1206. PubMed ID: 36437393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small-molecule inhibitors of Slack potassium channels as potential therapeutics for childhood epilepsies.
    M Qunies A; A Emmitte K
    Pharm Pat Anal; 2022 Mar; 11(2):45-56. PubMed ID: 35369761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aberrant epilepsy-associated mutant Nav1.6 sodium channel activity can be targeted with cannabidiol.
    Patel RR; Barbosa C; Brustovetsky T; Brustovetsky N; Cummins TR
    Brain; 2016 Aug; 139(Pt 8):2164-81. PubMed ID: 27267376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two Patients With KCNT1-Related Epilepsy Responding to Phenobarbital and Potassium Bromide.
    Datta AN; Michoulas A; Guella I; ; Demos M
    J Child Neurol; 2019 Oct; 34(12):728-734. PubMed ID: 31208268
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment Responsiveness in KCNT1-Related Epilepsy.
    Fitzgerald MP; Fiannacca M; Smith DM; Gertler TS; Gunning B; Syrbe S; Verbeek N; Stamberger H; Weckhuysen S; Ceulemans B; Schoonjans AS; Rossi M; Demarquay G; Lesca G; Olofsson K; Koolen DA; Hornemann F; Baulac S; Rubboli G; Minks KQ; Lee B; Helbig I; Dlugos D; Møller RS; Bearden D
    Neurotherapeutics; 2019 Jul; 16(3):848-857. PubMed ID: 31054119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disease-causing Slack potassium channel mutations produce opposite effects on excitability of excitatory and inhibitory neurons.
    Wu J; Quraishi IH; Zhang Y; Bromwich M; Kaczmarek LK
    Cell Rep; 2024 Mar; 43(3):113904. PubMed ID: 38457342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quinidine therapy and therapeutic drug monitoring in four patients with KCNT1 mutations.
    Yoshitomi S; Takahashi Y; Yamaguchi T; Oboshi T; Horino A; Ikeda H; Imai K; Okanishi T; Nakashima M; Saitsu H; Matsumoto N; Yoshimoto J; Fujita T; Ishii A; Hirose S; Inoue Y
    Epileptic Disord; 2019 Feb; 21(1):48-54. PubMed ID: 30782581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early Treatment with Quinidine in 2 Patients with Epilepsy of Infancy with Migrating Focal Seizures (EIMFS) Due to Gain-of-Function KCNT1 Mutations: Functional Studies, Clinical Responses, and Critical Issues for Personalized Therapy.
    Dilena R; DiFrancesco JC; Soldovieri MV; Giacobbe A; Ambrosino P; Mosca I; Galli MA; Guez S; Fumagalli M; Miceli F; Cattaneo D; Darra F; Gennaro E; Zara F; Striano P; Castellotti B; Gellera C; Varesio C; Veggiotti P; Taglialatela M
    Neurotherapeutics; 2018 Oct; 15(4):1112-1126. PubMed ID: 30112700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of response to quinidine in KCNT1-related neonatal epilepsy.
    Numis AL; Nair U; Datta AN; Sands TT; Oldham MS; Patel A; Li M; Gazina E; Petrou S; Cilio MR
    Epilepsia; 2018 Oct; 59(10):1889-1898. PubMed ID: 30182418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KCNT1-related epilepsy: An international multicenter cohort of 27 pediatric cases.
    Borlot F; Abushama A; Morrison-Levy N; Jain P; Puthenveettil Vinayan K; Abukhalid M; Aldhalaan HM; Almuzaini HS; Gulati S; Hershkovitz T; Konanki R; Lingappa L; Luat AF; Shafi S; Tabarki B; Thomas M; Yoganathan S; Alfadhel M; Arya R; Donner EJ; Ehaideb SN; Gowda VK; Jain V; Madaan P; Myers KA; Otsubo H; Panda P; Sahu JK; Sampaio LPB; Sharma S; Simard-Tremblay E; Zak M; Whitney R
    Epilepsia; 2020 Apr; 61(4):679-692. PubMed ID: 32167590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and molecular characterization of
    McTague A; Nair U; Malhotra S; Meyer E; Trump N; Gazina EV; Papandreou A; Ngoh A; Ackermann S; Ambegaonkar G; Appleton R; Desurkar A; Eltze C; Kneen R; Kumar AV; Lascelles K; Montgomery T; Ramesh V; Samanta R; Scott RH; Tan J; Whitehouse W; Poduri A; Scheffer IE; Chong WKK; Cross JH; Topf M; Petrou S; Kurian MA
    Neurology; 2018 Jan; 90(1):e55-e66. PubMed ID: 29196579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impaired motor skill learning and altered seizure susceptibility in mice with loss or gain of function of the Kcnt1 gene encoding Slack (K
    Quraishi IH; Mercier MR; McClure H; Couture RL; Schwartz ML; Lukowski R; Ruth P; Kaczmarek LK
    Sci Rep; 2020 Feb; 10(1):3213. PubMed ID: 32081855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Epilepsy-Associated KCNT1 Mutation Enhances Excitability of Human iPSC-Derived Neurons by Increasing Slack K
    Quraishi IH; Stern S; Mangan KP; Zhang Y; Ali SR; Mercier MR; Marchetto MC; McLachlan MJ; Jones EM; Gage FH; Kaczmarek LK
    J Neurosci; 2019 Sep; 39(37):7438-7449. PubMed ID: 31350261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KCNT1-positive epilepsy of infancy with migrating focal seizures successfully treated with nonnarcotic antitussive drugs after treatment failure with quinidine: A case report.
    Takase C; Shirai K; Matsumura Y; Watanabe T; Watanabe A; Hirasawa-Inoue A; Mizuguchi T; Matsumoto N; Sugai K; Hayashi M
    Brain Dev; 2020 Sep; 42(8):607-611. PubMed ID: 32505479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does age affect response to quinidine in patients with KCNT1 mutations? Report of three new cases and review of the literature.
    Abdelnour E; Gallentine W; McDonald M; Sachdev M; Jiang YH; Mikati MA
    Seizure; 2018 Feb; 55():1-3. PubMed ID: 29291456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Phe932Ile mutation in KCNT1 channels associated with severe epilepsy, delayed myelination and leukoencephalopathy produces a loss-of-function channel phenotype.
    Evely KM; Pryce KD; Bhattacharjee A
    Neuroscience; 2017 May; 351():65-70. PubMed ID: 28366665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Functional Properties, Physiological Roles, Channelopathy and Pharmacological Characteristics of the Slack (KCNT1) Channel.
    Zhang Q; Liu Y; Xu J; Teng Y; Zhang Z
    Adv Exp Med Biol; 2021; 1349():387-400. PubMed ID: 35138624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KCNT1 gain of function in 2 epilepsy phenotypes is reversed by quinidine.
    Milligan CJ; Li M; Gazina EV; Heron SE; Nair U; Trager C; Reid CA; Venkat A; Younkin DP; Dlugos DJ; Petrovski S; Goldstein DB; Dibbens LM; Scheffer IE; Berkovic SF; Petrou S
    Ann Neurol; 2014 Apr; 75(4):581-90. PubMed ID: 24591078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NBI-921352, a first-in-class, Na
    Johnson JP; Focken T; Khakh K; Tari PK; Dube C; Goodchild SJ; Andrez JC; Bankar G; Bogucki D; Burford K; Chang E; Chowdhury S; Dean R; de Boer G; Decker S; Dehnhardt C; Feng M; Gong W; Grimwood M; Hasan A; Hussainkhel A; Jia Q; Lee S; Li J; Lin S; Lindgren A; Lofstrand V; Mezeyova J; Namdari R; Nelkenbrecher K; Shuart NG; Sojo L; Sun S; Taron M; Waldbrook M; Weeratunge D; Wesolowski S; Williams A; Wilson M; Xie Z; Yoo R; Young C; Zenova A; Zhang W; Cutts AJ; Sherrington RP; Pimstone SN; Winquist R; Cohen CJ; Empfield JR
    Elife; 2022 Mar; 11():. PubMed ID: 35234610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.